September 25, 2020 -- Biovica has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA) for its DiviTumTKa breast cancer test.
The 510(k) submission follows a successful trial that analyzed data from over 400 U.S. and Canadian patients with advanced breast cancer. The test measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. All patients had hormone receptor-positive disease.
DiviTumTKa is currently sold as research use only, but Biovica plans to make the test available to breast cancer patients in early 2021, the firm said.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current